Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

E7080 in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2014 by Eisai Inc..
Recruitment status was  Active, not recruiting
Quintiles, Inc.
Information provided by (Responsible Party):
Eisai Inc. Identifier:
First received: May 21, 2010
Last updated: August 19, 2014
Last verified: August 2014
No Study Results Posted on for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: August 2014
  Primary Completion Date: August 2013 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: August 19, 2014